Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced Gastric and Colorectal Cancer with FGFR Alterations
NCT05202236Phase 2Unknown
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in gastric cancer (GC), colorectal cancer (CRC) and gastroesophageal junction cancer. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
pemigatinib
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05202236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202236.